Author Archives: Warren Woessner

Senate Subcommittee on IP Feels our PAIN

Posted on June 6, 2019 by Warren Woessner

In lengthy hearings conducted by the Senate Subcommittee on Intellectual Property (of the Committee on the Judiciary) on June 4th and 5th (Parts I and II; Part III will be held on June 11th), the Subcommittee, chaired by Senators Tillis … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Chisum Patent Academy – Seattle Seminar, August 2019

Posted on May 29, 2019 by Warren Woessner

Guest Post from the Chisum Patent Academy. Join us this Summer in beautiful Seattle, Washington for Critical Patent Law Updates! Registration is now open for our remaining advanced patent law seminar of 2019.  August 8 (Thurs) – August 9 (Fri) … Continue reading →

Posted in Conferences and Classes | Leave a comment

Bipartisan “Draft Bill” to Amend ss. 100, 101 and 112 Released for Comment

Posted on May 24, 2019 by Warren Woessner

On Wednesday, Senators Tillis and Coons, along with Reps. Collins, Johnson and Stivers released a draft, bipartisan bill to amend ss.100 and 101 to void the “judicial exceptions” to patent eligibility. Section 112(f) was also amended to tighten up the … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | Leave a comment

Novartis v. West-Ward – Lead Compound Analysis v. Motivation to Combine

Posted on May 20, 2019 by Warren Woessner

In Novartis Pharm. v. West-Ward Pharm., Appeal no. 2018-1434 (Fed. Cir., May 12, 2019), a three judge panel of Stoll, Plager and Clevenger affirmed the district court’s ruling that the claims of Novartis’ U.S. Pat. No. 8,410,131, directed to using … Continue reading →

Posted in Obviousness | Tagged , , , , , , | Leave a comment